Exai Bio says novel RNA and AI-driven platform can detect early breast cancer

Exai Bio, a leader in healthcare innovation, announced groundbreaking data showcasing the efficacy of its novel RNA-based and AI-driven liquid biopsy platform in detecting breast cancer at its earliest stages. The platform’s precision in identifying small tumors, including ductal carcinoma in situ (DCIS), using a standard blood sample, marks a significant advancement in cancer screening.

Early Breast Cancer Detection with High Accuracy

In a recent early detection study, Exai Bio’s platform demonstrated a sensitivity of 87% for stage I breast cancer and 81% for tumors sized T1a-b (10 mm or smaller), both at 90% specificity. The overall sensitivity across all invasive breast cancer stages was 88% at 90% specificity, surpassing any DNA-based liquid biopsy performance. For DCIS, the platform showed a sensitivity of 78% at the same specificity, presenting a compelling case for its use in early detection.

Pioneering Liquid Biopsy Technology by Exai Bio Sets New Standards in Breast Cancer Screening

Overcoming Limitations of Traditional Methods

Traditional breast cancer screening methods like mammography, though widely used, have limitations, especially in cases of dense breast tissue, small tumor sizes, and imaging anomalies. These limitations often lead to false negatives and delayed diagnosis. Exai Bio’s platform mitigates these issues, offering a more accessible and potentially more frequent screening method.

A Complementary Solution to Mammography

Pat Arensdorf, Chief Executive Officer of Exai Bio, emphasized the platform’s role as a powerful complementary solution to mammography. This is particularly significant for the millions of women with dense breast tissue, where traditional methods may fall short. Exai Bio’s platform stands out by detecting the smallest tumors and earliest stages of disease, challenging the limitations of DNA-based liquid biopsy approaches.

Innovations in RNA Sequencing and AI

Exai’s platform employs RNA sequencing to identify cancer-associated, small non-coding RNAs, known as orphan non-coding RNAs (oncRNAs). These oncRNAs, secreted from living cancer cells, are stable and abundant in the blood of cancer patients. Combined with proprietary AI technology, Exai Bio’s platform offers superior sensitivity, specificity, and the ability to monitor dynamic changes in tumor biology over time.

Broad Applications in Cancer Care

Exai Bio’s universal platform holds potential across various cancer care settings, including screening, early detection, monitoring, molecular residual disease, and therapy selection. This marks a paradigm shift in how cancers like breast cancer are detected and managed, offering hope for improved patient outcomes through early intervention.